Production, quality control and pharmacokinetic studies of 177Lu-EDTMP for human bone pain palliation therapy trials

Iranian Journal of Pharmaceutical Research

Volumn 11, Issue 1, 2012, Pages 137-144

  Bahrami Samani, Ali ^a   Anvari, Akbar ^b   Jalilian, Amir Reza ^a   Shirvani Arani, Simindokht ^a   Yousefnia, Hassan ^a   Aghamiri, Mahmoud Reza ^b   Ghannadi Maragheh, Mohammad ^a  

^a NUCLEAR SCIENCE AND TECHNOLOGY RESEARCH INSTITUTE   (Iran)

^b SHAHID BEHESHTI UNIVERSITY   (Iran)

Author keywords

Biodistribution; Pharmacokinetic; Quality control; Radiopharmaceutical

Indexed keywords

LUTETIUM 177 ETHYLENEDIAMINETETRAMETHYLENE PHOSPHONIC ACID; RADIOPHARMACEUTICAL AGENT; SAMARIUM 153; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; BONE PAIN; DRUG DISTRIBUTION; DRUG QUALITY; DRUG SYNTHESIS; NEUTRON RADIATION; NONHUMAN; QUALITY CONTROL; RADIOCHEMISTRY; RAT; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

EID: 84858591252     PISSN: 17350328     EISSN: 17266890     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Serafini AN. Therapy of metastatic bone pain. J. Nucl. Med. (2001) 42: 895-906.
2. Bayouth JE, Macey DJ, Kasi LP and Fossella FV. Dosimetry and toxicity of Samarium-153-EDTMP administered for bone pain to skeletal metastases. J. Nucl. Med. (1994) 35: 63-69.
3. Campa JA and Rayne R. The management of intractable bone pain: A clinician's perspective, Semin. Nucl. Med. (1992) 22: 3-10.
4. Eary JF, Collin C, Stabin M, Vernon C, Petersdorf S, Baker M, Hartnett S, Ferency S, Addison SJ and Appelbaum F. Samarium-153-EDTMP biodistribution and dosimetry estimation. J. Nucl. Med. (1993) 34: 1031-1036.
5. Bodei L, Ferone D, Grana CM, Cremonesi M, Signore A, Dierckx RA and Paganelli G. Peptide receptor therapies in neuroendocrine tumors. J. Endocrinol. Invest. (2009) 32: 360-9.
6. Michel RB, Andrews PM, Rosario AV, Goldenberg DM and Mattes MJ. 177Lu-antibody conjugates for single-cell kill of B-lymphoma cells in-vitro and for therapy of micrometastases in-vivo. Nucl. Med. Biol. (2005) 32: 269-78.
7. 177Lu-EDTMP: a viable bone pain palliative in skeletal metastasis. Cancer Biother. Radiopharm. (2008) 23: 202-13.
8. 177Lu-labelled hydroxyapatite as a promising agent for radiation synovectomy of small joints. Nucl. Med. Commun. (2006) 27: 661-8.
9. 177Lu-labeled hydroxyapatite particles for possible use in the therapy of liver cancer. Nucl. Med. Biol. (2008) 35: 589-97.
10. International Atomic Energy Agency (IAEA). Manual for reactor produced radioisotopes. IAEA-TECDOC-1340. IAEA, Austria (2003).
11. Moedritzer K and Irani RR. Direct synthesis of α-aminomethyl phosphonic acid: Mannich type reactions with o-phosphorus acid. J. Org. Chem. (1966) 31: 1603-1607.
12. EANM Radiopharmacy Committee. Guidelines on Current Good Radiopharmacy, Practice (Cgrpp) in the preparation of radiopharmaceuticals. Version 2. The Committee Brussels (2007) 112-115.
13. Du XL, Zhang TL, Yuan L, Zhao YY, Li RC, Wang K, Yan SC, Zhang L, Sun H and Qian ZM. Complexation of ytterbium to human transferrin and its uptake by K562 cells. Eur. J. Biochem. (2002) 269: 6082-90.
14. Sohaib M, Ahmad M, Jehangir M and Perveen A. Ethylenediaminetetramethylene phosphonic acid labeled with various β(-)-emitting radiometals: Labeling optimization and animal biodistribution. Cancer Biother. Radiopharm. (2011) 26: 159-64.
15. 177Lu-EDTMP. A potential bone pain palliation agent. Nucl. Med. Biol. (2010) 37: 215-26.
16. Alavi MS. Clinical trial project: Lu-177-HEDMP for Bone Pain Palliation of Bone Metastasis in Breast Cancer [Project]. Shiraz, Shiraz University of Medical Sciences, Nuclear Medicine Center (2010).